Targeted Treatment of Advanced Endometrial Cancer: Focus on Pembrolizumab

Endometrial cancer (EC) accounts for 2% of all new cancers. Advanced forms have a poor prognosis with barely 17% 5-year survival. The last few years improved our knowledge of EC with a new molecular classification derived from The Cancer Genome Atlas (TCGA). They are now divided between POLE mutant,...

Descripción completa

Detalles Bibliográficos
Autores principales: El-ghazzi, Nathan, Durando, Xavier, Giro, Alexia, Herrmann, Tressie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243542/
https://www.ncbi.nlm.nih.gov/pubmed/37288137
http://dx.doi.org/10.2147/OTT.S368050

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243542/
https://www.ncbi.nlm.nih.gov/pubmed/37288137
http://dx.doi.org/10.2147/OTT.S368050

Ejemplares similares